Redsense Medical’s international PCT application for the Smart Bandage is now published
Redsense Medical AB announces that the Company’s PCT application for a first smart wound care invention now is published.
On 6 February 2020, Redsense’s previously announced PCT application no. PCT/SE2019/050721 was published under no. WO2020027716A1, and is now available for everyone to read. The technology involves optical measuring of physiological and biological parameters and is a key component in the smart wound care solutions that Redsense Medical is developing.
The PCT application, based on the previously approved Swedish patent for smart bandage (‘A Device for measuring a property of a measurement object by luminescence’) was filed on 1 August 2019. As previously disclosed by Redsense Medical, an international search report (ISR) was received on 9 October 2019, and the written opinion was entirely favourable with regard to all examined aspects of patentability (novelty, inventive step and industrial applicability). The Company is currently also awaiting the patent letter for the granted Swedish patent, which is expected to be issued within the next couple of weeks.
”With our ground-breaking optical technology for measuring blood and exudate, we will be able to contribute to individualized care all over the world and offer a truly unique wound care solution. The next step is to nationalize the PCT application in specific geographies,” says Patrik Byhmer, CEO of Redsense Medical AB. “We are looking to protect the invention in all relevant markets – the United States, Europe, China, Australia, Canada, India, Japan, Korea, etc.”
The nationalization must be carried out before 3 February 2021.
The published PCT application is available here: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020027716&_cid=P11-K7G2NW-54443-1
What is PCT?
The Patent Cooperation Treaty (PCT) is an international agreement allowing you to file a single application in one language and get an international filing date. That means the application is considered as filed in all the PCT contracting states, more than 140, on that date. A PCT application itself does not lead to a patent, rather to an international search and a written opinion regarding patentability (novelty, inventive step and industrial applicability).
The PCT is administered by the UN agency World Intellectual Property Organization (WIPO) with its headquarters in Geneva. A PCT application is dealt with in one or two phases. First, a mandatory international search is carried out (phase I), which results in an International Search Report (ISR). Then, the applicant can request an optional international preliminary examination (phase II), which results in an International Preliminary Report on Patentability (IPRP Chapter II).
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.